RBC Life Sciences (RBCL) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 09, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	RBC LIFE SCIENCES, INC.
Entity Central Index Key	830052
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		2,212,350
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$1,053,433

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$1,921,349	$3,745,684
Accounts receivable, net of allowance for doubtful accounts of $35,219 and $28,000, respectively	1,285,843	907,287
Inventories	4,799,083	5,141,509
Deferred income taxes	376,925	429,640
Prepaid expenses and other current assets	464,020	793,548
Total current assets	8,847,220	11,017,668
Property and equipment, net of accumulated depreciation	4,683,496	4,169,078
Goodwill	2,221,347	2,263,458
Other intangible assets, net of accumulated amortization	39,975	37,979
Other assets	203,906	45,327
Total assets	15,995,944	17,533,510
Current liabilities
Accounts payable, trade	2,310,192	1,608,000
Accrued liabilities	1,420,050	1,156,818
Current maturities of long-term obligations	229,538	212,474
Deferred revenue	2,147,290	3,677,893
Total current liabilities	6,107,070	6,655,185
Long-term obligations, less current maturities	906,809	1,136,347
Deferred income taxes	556,440	727,660
Commitments and contingencies
Shareholders' equity
Common stock, $0.001 par value; authorized 50,000,000 shares; 2,212,350 shares issued and outstanding in 2014 and 2013, respectively (see Note B regarding Stock Splits)	2,212	2,212
Additional paid-in capital (see Note B regarding Stock Splits)	13,713,630	13,711,522
Accumulated deficit	-5,417,092	-4,814,281
Accumulated other comprehensive income	126,875	114,865
Total shareholders' equity	8,425,625	9,014,318
Total liabilities and shareholders' equity	$15,995,944	$17,533,510

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Less allowance for doubtful accounts	$35,219	$28,000
Shareholders' equity
Common stock par value (in dollars per share)	$0.00	$0.00
Common stock shares authorized	50,000,000	50,000,000
Common stock shares issued	2,212,350	2,212,350
Common stock shares outstanding	2,212,350	2,212,350

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net sales	$28,270,448	$25,470,934
Cost of sales	12,632,375	13,459,279
Gross profit	15,638,073	12,011,655
Operating expenses
General and administrative	11,062,649	9,344,628
Distributor commissions	4,697,802	2,785,568
Depreciation and amortization	502,888	506,083
Total operating expenses	16,263,339	12,636,279
Operating loss	-625,266	-624,624
Interest expense	95,719	111,617
Loss before income taxes	-720,985	-736,241
Income tax benefit	-118,174	-236,236
Net loss	-602,811	-500,005
Foreign currency translation adjustment	12,010	-3,952
Comprehensive loss	($590,801)	($503,957)
Basic (usd per share)	($0.27)	($0.23)
Diluted (usd per share)	($0.27)	($0.23)
Basic (shares)	2,212,350	2,218,757
Diluted (shares)	2,212,350	2,218,757

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Shareholders' equity, beginning of period at Dec. 31, 2012	$9,515,498	$2,223	$13,708,736	($4,314,278)	$118,817
Common stock, beginning of period (shares) at Dec. 31, 2012		2,222,883
Comprehensive income (loss)
Net loss	-500,005			-500,005
Foreign currency translation adjustment	-3,952				-3,952
Comprehensive loss	-503,957
Share-based compensation	20,648		20,648
Share Repurchase & Other (shares)	-10,533
Share Repurchase & Other	-17,871	-11	-17,862	2
Shareholders' equity, beginning of period at Dec. 31, 2013	9,014,318	2,212	13,711,522	-4,814,281	114,865
Common stock, end of period (shares) at Dec. 31, 2013	2,212,350	2,212,350
Comprehensive income (loss)
Net loss	-602,811			-602,811
Foreign currency translation adjustment	12,010				12,010
Comprehensive loss	-590,801
Share-based compensation	2,108		2,108
Shareholders' equity, beginning of period at Dec. 31, 2014	$8,425,625	$2,212	$13,713,630	($5,417,092)	$126,875
Common stock, end of period (shares) at Dec. 31, 2014	2,212,350	2,212,350

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	($602,811)	($500,005)
Adjustments to reconcile net loss to net cash provided by operating activities
Depreciation and amortization	579,900	588,287
Loss on disposition of assets	0	2,529
Deferred income taxes	-125,173	-235,460
Share-based compensation	2,108	20,648
Change in operating assets and liabilities
Accounts receivable	-378,667	-30,017
Inventories	317,630	-66,178
Prepaid expenses and other current assets	288,053	-91,918
Other assets	-161,606	-15,946
Accounts payable, trade	709,636	116,517
Accrued liabilities	293,731	55,086
Deferred revenue	-1,530,533	450,689
Net cash provided (used) by operating activities	-607,732	294,232
Cash flows from investing activities
Purchase of property and equipment	-1,074,436	-267,055
Net cash used in investing activities	-1,074,436	-267,055
Cash flows from financing activities
Redemption of common stock	0	-17,872
Payments of long-term obligations	-212,474	-196,678
Net cash used in financing activities	-212,474	-214,550
Effect of exchange rate changes on cash flows	70,307	36,970
Net decrease in cash and cash equivalents	-1,824,335	-150,403
Cash and cash equivalents at beginning of year	3,745,684	3,896,087
Cash and cash equivalents at end of year	1,921,349	3,745,684
Supplemental cash flow disclosures
Interest paid	97,092	112,887
Income taxes paid (refunded), net	$39,760	($169,165)

Nature_of_Operations_and_Organ

Nature of Operations and Organization	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Organization	NATURE OF OPERATIONS AND ORGANIZATION
	RBC Life Sciences, Inc. (along with its subsidiaries, sometimes hereinafter referred to collectively as “RBC” or the “Company”) is engaged in the marketing and distribution of nutritional supplements and personal care products (collectively “Nutritional Products”) through subsidiaries in North America and Southeast Asia.  This product line is marketed under the “RBC Life” brand name and is sold in North America, Southeast Asia and Australia through a network of distributors that are referred to as “Associates.”  The Associates are independent contractors who purchase products for personal use, purchase products for resale to retail customers and sponsor other individuals as Associates.  Accordingly, Associates may be product consumers only or they may also seek to derive compensation both from the direct sales of products and from sales generated by sponsored Associates.
	RBC also markets its Nutritional Products in certain international markets through license arrangements.  The licensees are third parties who are granted exclusive rights to distribute RBC products in their respective territories and, for the most part, distribute these products through an independent distributor network in a licensed territory.  Under these arrangements, the independent distributor network in a licensed territory is compensated by the licensee in accordance with a compensation plan similar to the one used by RBC for its Associates.
	In addition to its Nutritional Products, RBC also markets a line of wound care products (“Medical Products”) under the MPM Medical brand name through a U.S. subsidiary.  Medical Products are primarily distributed in the U.S. to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation and Reporting - The consolidated financial statements include the accounts of RBC and its wholly owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.  Subsequent events were evaluated through the issuance date of the financial statements.
	Cash and Cash Equivalents - The Company regularly holds cash deposits in foreign bank accounts in connection with its foreign operations.  At December 31, 2014 and 2013, $833,000 and $1,164,000, respectively, were held in foreign banks. For purposes of the consolidated statements of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company includes in its cash and cash equivalents credit card payments due from its credit card processors.
	The Company maintains certain cash balances at a bank located in the U.S. which at times may exceed insured limits. The Company maintains an agreement with this bank that provides certain collateral as security against the possibility of losses in excess of insured limits. The Company has not experienced any losses with respect to these accounts and believes it is not exposed to any significant credit risk.
	Accounts Receivable - The Company’s accounts receivable arise in the normal course of business and primarily relate to sales of Medical Products to various businesses and individuals.  Accounts receivable are generally due within 30, 45 or 60 days and are stated at amounts due from customers net of an allowance for doubtful accounts.
	Accounts outstanding longer than the contractual payment terms are considered past due.  The Company determines its allowance by considering a number of factors including the length of time accounts are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company and the industry as a whole.  The Company charges accounts receivable against the allowance when they become uncollectible, and any payments subsequently received on such accounts are credited to the allowance for doubtful accounts.
	Inventories - Inventories consisting of raw materials and bulk products, packaging materials and finished goods are stated at the lower of cost or market.  The cost of inventories is determined using the first in, first out method.
	Property and Equipment - Property and equipment are recorded at cost. Depreciation and amortization are provided over the estimated useful lives of the related assets, principally on the straight-line method, ranging from three to 25 years.
	Intangible Assets and Amortization - Goodwill and other intangible assets with indefinite useful lives are not amortized, but are reviewed annually for impairment or when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Intangible assets with finite lives are amortized over their useful lives.  At December 31, 2014 and 2013, the Company’s intangible assets with finite lives consisted of copyrights, trademarks and other registrations, a business license and other intangibles, all of which are amortized over an average life of 19 years except the business license, which is being amortized over a life of one year.
	The Company has designated year end as the date of its annual goodwill impairment test.  The Company tests goodwill for impairment by comparing the carrying value of a reporting unit, including goodwill, to the fair value of the unit.  Fair value is determined by estimating the present value of future cash flows and the value of comparable companies based on sales multiples.  An impairment loss would be recognized if the carrying value of a reporting unit exceeds the implied fair value.  To date, the Company has not recognized any impairment losses related to the carrying value of its goodwill. See Note L for a discussion of the fair value assumptions used for assessing goodwill for impairment.
	Impairment of Long-Lived Assets - Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
	Stock Splits - On August 9, 2013, the Company completed a 1-for-500 reverse stock split (the "Reverse Split"), whereby each 500 shares of the Company's issued and outstanding shares of common stock was converted into one whole share of new common stock (the "New Common Stock"). No fractional shares were issued in connection with the Reverse Split. In lieu of issuing fractional shares, the Company agreed to pay $0.1691 per share to shareholders upon presentation of documents evidencing ownership of the fractional shares.
	Immediately following the Reverse Split, the Company completed a 50-for-1 forward stock split (the "Forward Split" and together with the Reverse Split, the "Stock Splits") whereby each share of New Common Stock was converted into 50 shares of common stock.
	The Company's common stock began trading at the split-adjusted price on August 12, 2013. All share numbers and per share amounts presented reflect the Stock Splits. Amounts recorded as common stock and additional paid in capital within the shareholders' equity section of the consolidated balance sheets have been restated to reflect the impact of the Stock Splits.
	Revenue Recognition and Deferred Revenue - Sales are recorded when products are shipped, which is the point the risks and rewards of ownership pass to the customer. Sales include amounts billed to customers for shipping and handling and are recorded net of sales taxes.  The Company generally requires a cash or credit card payment at the point of sale for Nutritional Products sold to its Associates.  With regard to orders received from its third-party licensees, the Company generally requires the licensee to make a cash deposit equal to 25% to 50% of the order at the time an order is placed, and to pay the remaining balance when the products are segregated in the Company's warehouse and ready to ship; however, sales are not recognized until the products are shipped. Deposits and payments received for unshipped products are recorded as “deferred revenue.”
	Prior to August 1, 2014, the Company’s agreement with its principle licensee, Coral Club International, Inc. ("CCI"), provided that CCI pay to the Company a monthly royalty, which was calculated as a specified percentage of its sales, as defined, in the territory covered by the license agreement.  As more fully described in Note P, in August 2014, the Company entered into a new two-year license agreement with CCI that restructured the royalty calculations. Under the new arrangement, the prices at which products are sold to CCI were marked up to include the royalty; accordingly royalties are no longer due upon sale of the products by CCI. To affect this transition, the Company recognized royalties of $941,000 on a one-time basis, which royalties will be paid over an 18-month period beginning October 2014. Of this $941,000 in royalties, approximately $476,000 was recorded as royalty revenue in the third quarter of 2014 while the remainder was recorded as deferred revenue pending shipment of the related products. Royalty revenue recorded in connection with the Company's licensee agreements was recorded as sales and amounted to $1,444,000 and $1,801,000 in 2014 and 2013, respectively.
	Distributor Commissions - Distributor commissions consist primarily of commissions paid to Associates in accordance with the Associate compensation plan.  These commissions are calculated based on the total monthly sales by the Associate and his or her downline organization.  Most commissions are paid to Associates monthly.  Sales incentives paid to Associates that represent rebates are recorded as a reduction of sales rather than distributor commission expense.  Associates can earn rebates if the amount of their personal monthly sales exceeds a threshold amount set forth under the Associate compensation plan.  Associate rebates recorded as a reduction of sales were $324,000 and $281,000 in 2014 and 2013, respectively.
	Income Taxes - The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred income tax assets and liabilities are provided based on the difference between the financial statement and tax bases of assets and liabilities as measured by the currently enacted tax rates in effect for the years in which these differences are expected to reverse. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities. An allowance against deferred tax assets is recorded in whole or in part when it is more likely than not that such tax benefits will not be realized.
	At December 31, 2014 and 2013, the Company had no unrecognized tax benefits. The Company’s policy is to record any interest and penalties related to gross unrecognized tax benefits within its provision for income taxes.
	Earnings (Loss) Per Share - Basic earnings (loss) per common share is based upon the weighted average number of common shares outstanding during each period presented. Diluted earnings (loss) per share is based upon the weighted average number of common shares outstanding and, when dilutive, common shares issuable for stock options.
	Accounting Estimates - In preparing financial statements in conformity with accounting principles generally accepted in the U.S. ("US GAAP"), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues during the reporting period.  Actual results could differ from those estimates.
	Financial Instruments - The carrying value of cash, interest-bearing deposits, accounts receivable and payable, accrued liabilities and lines of credit approximate fair value due to the short-term maturities of these assets and liabilities. Fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.  At December 31, 2014, fair value of fixed-rate long-term debt was $1,226,000, which was $90,000 above the carrying value of $1,136,000.  At December 31, 2013, fair value of fixed-rate long-term debt was $1,469,000, which was $120,000 above the carrying value of $1,349,000. See Note L for a discussion of the fair value assumptions used to determine the fair value of our fixed-rate long-term debt.
	Segment Information - The Company’s operations involve two operating segments:  the Nutritional Products segment and the Medical Products segment.  Nutritional Products are developed and distributed to a network of independent Associates operating primarily in North America, Southeast Asia and Australia and to licensees operating in certain other countries.  Medical Products are developed and sold primarily throughout the U.S. through medical/surgical supply dealers and pharmaceutical distributors to medical institutions such as hospitals, nursing homes and pharmacies.
	Product Return Policy - Up to one year from the date of purchase, Nutritional Products that are unused and resalable may be returned by an Associate for a refund equal to 100% of the sales price to the Associate less a 10% restocking fee and commissions paid. The return of product by an Associate, other than product damaged at the time of receipt, may result in cancellation of the distributorship. Generally, unused Medical Products may be returned up to six months from date of purchase for a refund equal to 100% of the sales price less a 25% restocking fee.  Returned products damaged during shipment are replaced by the Company.  Nutritional Products purchased by licensees may not be returned to the Company for a refund except in the case of a product defect.
	Advertising - Advertising expense is charged to operations when incurred.  Advertising expenses were $37,000 and $44,000 in 2014 and 2013, respectively.
	Translation of Foreign Currencies - All assets and liabilities of foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect at the consolidated balance sheet date.  Revenue and expense accounts are translated at weighted average exchange rates. Translation gains and losses are reflected as a component of other comprehensive income in shareholders' equity.  Gains and losses on foreign currency transactions are included in the consolidated statements of comprehensive income. In 2014, the Company recorded a loss on foreign currency transactions of 220,000. In 2013, the Company recorded a loss on foreign currency transactions of 66,000, which loss was charged to general and administrative expenses.
	Other Comprehensive Income (Loss) - Other comprehensive income (loss) refers to revenues, expenses, gains and losses that under US GAAP are included in comprehensive income (loss) but are excluded from net earnings (loss) as the amounts are recorded directly as an adjustment to shareholders’ equity.  The Company’s other comprehensive income is attributed to translation gains or losses of foreign currencies.
	Share-Based Compensation - The Company recognizes share-based compensation expense based on the fair value of share-based awards.  Share-based compensation is estimated at the grant date based on the fair value of the awards expected to vest and recognized as expense ratably over the requisite service period of the award. The Company uses the Black-Scholes valuation model to estimate fair value of share-based awards, which requires various assumptions including estimating stock price volatility, risk-free interest rate and expected life.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company does not believe ASU No. 2014-09 will have a material effect on its financial position and results of operations.
	In August 2014, FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern. ASU No. 2014-15 provides guidance regarding management’s responsibility to evaluate whether there exists substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. ASU No. 2014-15 is effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. The Company does not believe ASU No. 2014-15 will have a material effect on its financial position and results of operations.

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Accounts Receivable	ACCOUNTS RECEIVABLE
	At December 31, 2014 and 2013, accounts receivable consist of the following:
		2014			2013
	Accounts receivable
	Trade	$	1,321,062		$	914,287
	Other	—			21,000
	Total	1,321,062			935,287
	Less allowance for doubtful accounts	35,219			28,000
	Net accounts receivable	$	1,285,843		$	907,287
	Changes in the Company’s allowance for doubtful accounts for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Beginning balance	$	28,000		$	27,417
	Bad debt provision	7,263			9,926
	Accounts written off	(44		)	(9,343		)
	Ending balance	$	35,219		$	28,000
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. In accordance with an arrangement approved by the Bankruptcy Court, the pre-petition accounts receivable balance of approximately $240,000 that was outstanding at December 31, 2013 was paid in full during 2014.
	As more fully described in Note P, in August 2014, the Company entered into a new two-year exclusive distributorship agreement with CCI pursuant to which the royalty calculations were restructured. Under the previous agreement, CCI paid the Company a monthly royalty calculated as a percentage of its sales of the Company's products. Under the new agreement, in lieu of the monthly royalty, the prices at which products are sold to CCI were marked to include the royalty so that no additional royalty will be due upon the sale of the Company's products by CCI. To affect the transition of royalty calculations from the previous agreement to the new agreement, the Company recorded a royalty receivable of $941,000, which is to be paid over an 18-month period beginning October 2014 in the amount of approximately $52,000 per month. The portion of this royalty receivable due after December 31, 2015 is classified as "Other assets" in the accompanying consolidated balance sheet.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	INVENTORIES
	At December 31, 2014 and 2013, inventories, which are stated at the lower of cost or market, consist of the following:
		2014		2013
	Raw materials and bulk products	$	370,333	$	371,863
	Packaging materials	253,700		135,138
	Finished goods	4,175,050		4,634,508
		$	4,799,083	$	5,141,509

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2014
Prepaid Expense, Current [Abstract]
Prepaid Expenses and Other Current Assets	PREPAID EXPENSES AND OTHER CURRENT ASSETS
	At December 31, 2014 and 2013, prepaid expenses and other current assets consist of the following:
		2014		2013
	Advances to Associate	$	—	$	339,603
	Advance payments to suppliers	151,365		202,682
	Certificates of deposit – restricted	73,270		79,909
	Prepaid insurance and other	239,385		171,354
	Total	$	464,020	$	793,548
	In 2013, the Company entered into agreements with an Associate to market Nutritional Products in Australia and certain Southeast Asia markets (the "Asia Marketing Agreements"). Pursuant to the Asia Marketing Agreements, the Company made cash advances to this Associate to support marketing and sales activities and establish product distribution facilities. These advances did not bear interest and were to be recovered from monthly marketing fees calculated as a percentage of sales that were generated in the Associate's markets.
	On July 30, 2013, in breach of Asia Marketing Agreements, the Associate notified the Company that he was unable to fulfill his financial obligations. At the date of the breach, the Company had advanced funds to this Associate totaling approximately $403,000. Following notice of the breach, the Company continued to fund the Asia operations initiated by this Associate and charged the funding to general and administrative expenses in the periods in which the expenses were incurred.
	On March 31, 2014, the Company formally terminated the Asia Marketing Agreements and, in lieu of payment due from the Associate on the outstanding advances, took possession of property and equipment and lease deposits valued at approximately $104,000 and $43,000, respectively. The balance of the advances outstanding at March 31, 2014 was charged to general and administrative expenses.
	At December 31, 2014 and 2013, the Company held certificates of deposit in the amount of approximately $73,000 and $80,000, respectively, which were pledged to secure surety bonds.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	PROPERTY AND EQUIPMENT
	At December 31, 2014 and 2013, property and equipment consist of the following:
		2014		2013
	Building and improvements	$	4,042,897	$	3,912,449
	Computer software and office equipment	3,536,399		2,592,382
	Warehouse equipment	254,034		254,034
	Automotive equipment	14,717		14,717
		7,848,047		6,773,582
	Less accumulated depreciation and amortization	4,305,724		3,745,677
		3,542,323		3,027,905
	Land	1,141,173		1,141,173
		$	4,683,496	$	4,169,078
	Depreciation expense totaled approximately $542,700 and $582,300 for the years ended December 31, 2014, and 2013, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS
	The Company measures its goodwill for impairment at the end of each year or in the event of an impairment indicator.  No impairment losses have been recognized as a result of this testing. See Note L for a discussion of the fair value assumptions used for assessing goodwill for impairment.
	Goodwill balances are summarized as follows:
			Gross				Accumulated
			Carrying				Amortization
			Value
	Balance, January 1, 2013		$	3,435,305			$	(1,137,285	)
	Currency translation adjustment		(67,442		)		32,880
	Balance, December 31, 2013		3,367,863				(1,104,405		)
	Currency translation adjustment		(82,173		)		40,062
	Balance, December 31, 2014		$	3,285,690			$	(1,064,343	)
	At December 31, 2014 and 2013, other intangible assets consist of the following:
			2014									2013
			Average		Gross				Accumulated			Average	Gross		Accumulated
			Life		Carrying				Amortization			Life	Carrying		Amortization
			(years)		Value							(years)	Value
	Copyrights, trademarks and other registrations		19		$	99,100			$	(70,690	)	19	$	99,100	$	(65,405	)
	Business license		1		37,193				(29,240		)	0	—		—
	Other		19		12,600				(8,988		)	19	12,600		(8,316		)
					$	148,893			$	(108,918	)		$	111,700	$	(73,721	)
	Amortization expense related to other intangible assets totaled approximately $37,200 and $6,000 for the years ended December 31, 2014 and 2013.  The aggregate estimated amortization expense for other intangible assets is as follows:
	Year ended December 31,
	2015	$	13,910
	2016	5,957
	2017	5,957
	2018	5,957
	2019	5,957
	Thereafter	2,237
		$	39,975

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES
	At December 31, 2014 and 2013, accrued liabilities consist of the following:
		2014		2013
	Distributor commissions	$	867,336	$	507,365
	Salaries and wages	468,192		502,303
	Sales and property taxes	73,954		83,159
	Interest	7,339		8,711
	Other	3,229		55,280
	Total	$	1,420,050	$	1,156,818

LongTerm_Obligations

Long-Term Obligations	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Obligations	LONG-TERM OBLIGATIONS
	At December 31, 2014 and 2013, long-term obligations consist of the following:
			2014		2013
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board of Directors		$	1,136,347	$	1,348,821
	Less – current maturities		229,538		212,474
			$	906,809	$	1,136,347
	Long-term obligation payments payable in the next five years are as follows:
	Year ended December 31,
	2015	$	229,538
	2016	247,973
	2017	267,889
	2018	289,403
	2019	101,544
		$	1,136,347

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2014
Share-based Compensation [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION
	All share numbers and per share amounts presented below reflect the Stock Splits. See Note B for additional information regarding the Stock Splits.
	Stock incentive plans - On July 1, 1998, the Company’s shareholders adopted the 1998 Stock Option Plan and reserved 50,000 shares of common stock for issuance under this plan.  Effective September 4, 2003, the Company’s shareholders adopted an amendment and restatement of this plan, which, among other things, increased the number of shares reserved under this plan to 350,000. This plan expired July 1, 2008 although options granted under this plan remain outstanding at December 31, 2014.
	On June 1, 2006, the Company’s shareholders adopted the 2006 Stock Incentive Plan (the “2006 Plan”) under which 250,000 shares of common stock were reserved for issuance.  The 2006 Plan provides for the issuance of non-qualified stock options, incentive stock options, restricted stock awards and stock appreciation rights, and permits grants to employees, non-employee directors and consultants of the Company.
	Generally, stock options granted under these plans vest over a period from four to five years and have a term of nine years.  Certain stock options granted under these plans were fully vested upon grant and certain options have terms of five years.
	Stock Option Accounting - The Company recognizes share-based compensation expense based on the fair value of share-based awards as estimated at the grant date.  Share-based compensation expense for 2014 and 2013 was approximately $2,100 and $20,600, respectively, and is classified as a general and administrative expense.  Tax benefits related to this expense were immaterial because virtually all share-based compensation resulted from grants of ISOs.  No tax benefit is recorded for an ISO unless upon exercise a disqualifying disposition occurs.  The Company will prospectively record any excess tax benefits from the exercise of stock options as cash flows from financing activities. There were no material excess tax benefits in 2014 or 2013.
	Fair Value - The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Year Ended December 31,
		2014		2013
		-1
	Weighted average expected life (years)	0		4.5
	Risk-free interest rate	—%		1.40%
	Expected volatility	—%		261.00%
	Expected dividend yield	—%		—%
	______________________
	(1) There were no option grants during this period.
	The weighted average expected life is based on the option term.  The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option.  The expected volatility is based on historical volatility rates.  The expected dividend yield is 0.0% since the Company has no history of paying dividends and currently has no plans to do so.
	Stock Option Activity - A summary of stock option activity for the two years ended December 31, 2014 is as follows:
		Options			Weighted-			Weighted-Average		Aggregate
					Average Exercise			Remaining		Intrinsic
					Price per Share			Contractual Term		Value
								(in years)
	Outstanding, January 1, 2013	86,126			$	4
	Granted	2,160			1.17
	Exercised	—			—
	Forfeited/canceled	(18,890	)		3.47
	Outstanding, December 31, 2013	69,396			4
	Granted	—			—
	Exercised	—			—
	Forfeited/canceled	(18,500	)		3.29
	Outstanding, December 31, 2014	50,896			$	4.35		2.8		$	—
	Exercisable, December 31, 2014	50,896			$	4.35		2.8		$	—
	A summary of the status of the Company’s non-vested stock options as of December 31, 2014 and 2013, and changes during the year then ended, is presented below:
		Year Ended December 31,
		2014						2013
		Shares			Weighted Average			Shares			Weighted Average
					Grant Date Fair						Grant Date Fair
					Value per Share						Value per Share
	Non-vested stock options at January 1,	14,750			$	2.68		19,976			$	2.9
	Non-vested stock options granted	—			—			2,160			1.14
	Vested stock options	—			—			(7,386	)		2.92
	Forfeited stock options	(14,750	)		2.68			—			—
	Non-vested stock options at December 31,	—			$	—		14,750			$	2.68
	Additional information related to stock options granted, vested and exercised for the two years ended December 31, 2014 is a follows:
		Year Ended December 31,
		2014				2013
	Grant date fair value of stock options granted	$	—			$	2,471
	Grant date fair value of stock options vested	—				21,586
	Intrinsic value of stock options exercised	—				—
	As of December 31, 2014, there was no unrecognized compensation cost related to stock option grants.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	The income tax benefit reconciled to the tax computed at the statutory federal rate of 34% is as follows:
		Year Ended December 31,
		2014			2013
	Federal income tax benefit at statutory rate	$	(245,135	)	$	(250,322	)
	State income taxes, net of federal benefit	1,682			(755		)
	Share-based compensation	716			6,759
	Effect of foreign operations, net of foreign tax credits	114,232			42,340
	R&D tax credits recognized	—			(35,417		)
	Other, net	10,331			1,159
	Income tax benefit	$	(118,174	)	$	(236,236	)
	Deferred tax assets and liabilities at December 31, 2014 and 2013 are comprised of the following:
		December 31,
		2014			2013
	Deferred tax assets related to:
	Inventories	$	281,155		$	289,818
	Accounts receivable and other assets	12,327			9,800
	Accrued liabilities	83,443			89,816
	Tax loss and tax credit carryforwards	603,018			583,787
	Other	16,446			16,349
		996,389			989,570
	Valuation allowance	(196,661		)	(214,479		)
	Net deferred tax assets	799,728			775,091
	Deferred tax liabilities related to:
	Property and equipment	(363,119		)	(462,221		)
	Intangible assets	(616,124		)	(610,890		)
	Deferred tax liabilities	(979,243		)	(1,073,111		)
	Net deferred tax liabilities	$	(179,515	)	$	(298,020	)
	Net current deferred tax assets	$	376,925		$	429,640
	Net long-term deferred tax liabilities	(556,440		)	(727,660		)
		$	(179,515	)	$	(298,020	)
	At December 31, 2014, the Company has U.S. federal net operating loss carryforwards of approximately $73,000 and tax credit carryforwards of approximately $170,000 that begin to expire in 2020, if not utilized. The Company also has net operating loss carryforwards totaling approximately $1,986,000 related to various foreign jurisdictions that begin to expire in 2016 if not utilized.
	The Company files federal income tax returns in the U.S. and certain foreign jurisdictions where the Company conducts operations and in certain U.S. state jurisdictions. The most significant taxing jurisdiction is the U.S. federal jurisdiction.  The Company’s 2010 through 2014 tax years remain subject to examination by the IRS for U.S. federal tax purposes.  As of December 31, 2014, no tax years were under examination in any taxing jurisdiction.
	Income tax expense (benefit) consists of the following:
		Year Ended December 31,
		2014			2013
	Current
	Federal	$	6,999		$	2,941
	Foreign	—			(3,717		)
	Deferred
	Federal	21,816			(196,484		)
	Foreign	(146,989		)	(38,976		)
	Income tax benefit	$	(118,174	)	$	(236,236	)

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS
	As defined in ASC 820, Fair Value Measurements, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect less transparent active market data, as well as internal assumptions. These two types of inputs create the following fair value hierarchy:
	· Level 1-Quoted prices for identical instruments in active markets
	· Level 2-Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose significant inputs are observable
	· Level 3-Instruments with significant unobservable inputs
	The fair value of the Company's fixed-rate long-term debt as described in the "Financial Instruments" section under Note B was determined based on quoted prices for similar instruments in active markets, which are considered to be Level 2 inputs within the fair value hierarchy.
	The Company has also performed the required impairment review related to goodwill, as described in Note B. A fair value-based methodology is used in testing the carrying value of goodwill, utilizing assumptions including: (1) a long-term projection of revenues and expenses; (2) estimated discounted future cash flows; (3) weighted-average cost of capital; (4) expected tax rate and (5) the enterprise value of comparable companies as a percentage of sales. Factors used in the valuation of goodwill include, but are not limited to, management's plans for future operations, recent operating results and discounted projected future cash flows. These factors are considered Level 3 inputs within the fair value hierarchy.

Commitments_and_Contingencies_

Commitments and Contingencies (Notes)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES
	Leases - The Company leases office and warehouse space and certain equipment using operating leases for various periods through 2018.  Rental expense under non-cancelable operating leases totaled $415,000 and $193,000 in 2014 and 2013, respectively.  Future minimum payments under non-cancelable operating leases are as follows:
	Year ended December 31,
	2015	$	452,354
	2016	354,981
	2017	135,813
	2018	7,029
		$	950,177
	Employee Arrangements - The Company has entered into employment agreements with certain of its key executives. In October, 2013, the Company entered into an employment agreement with the Company's then Chief Executive Officer. This agreement provided for employment through December 31, 2014, automatic renewal of employment for an additional one-year term unless either party provided notice of non-renewal and, upon termination of employment, a three-year consulting arrangement to be compensated at a specified portion of salary. The employment agreement was not renewed as of December 31, 2014.
	In December 2014, the Company entered into an employment agreement with the Company's current Chief Executive Officer with an initial term ending December 31, 2015. This agreement automatically renews for an additional one-year term at end of the initial term or any subsequent renewal term unless either party provides notice to the other 60 days prior to the last day of the then current term. Among other things, the agreement provides that if employment is terminated for certain reasons set forth in the agreement, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to the greater of (i) the remaining compensation due through the end of the current term or (ii) one-half of the annual base salary. In the event that the Company chooses not to renew the agreement, the Chief Executive Officer will be entitled to one-half of the annual base salary as severance.
	In December 2014 and January 2015, the Company entered into employment agreements with six other officers or members of the executive team, expiring December 31, 2015. These agreements generally replaced agreements which expired December 31, 2014. Among other things, the agreements provide that if employment is terminated for certain reasons set forth in the agreements, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to the greater of (i) the remaining compensation due through the end of the current term or (ii) one-half of the annual base salary.
	The Company’s employees can participate in an employee benefit plan under Section 401(k) of the Internal Revenue Code offered through its Professional Employer Organization.  This plan covers employees in the U.S. who are at least 18 years of age and have been employed by the Company longer than three months.  The Company makes discretionary matching contributions equal to 10% of the employees’ contributions.  Total matching contributions made by the Company during 2014 and 2013 were approximately $10,000 and $13,000, respectively.
	Litigation - The Company is from time to time engaged in routine litigation.  The Company regularly reviews all pending litigation matters in which it is involved and establishes reserves deemed appropriate by management.
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer accounted for 45% and 44% of Medical Products net sales in 2014 and 2013, respectively. On February 27, 2012, The Company was notified that this dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. According to its bankruptcy petition, this dealer filed its petition as the most effective means of stabilizing its finances as it resolves a reimbursement guidelines dispute with Medicare, which the dealer believes is improperly withholding payments. In a press release issued by the dealer at the time of the filing, the dealer stated that the Chapter 11 filing will allow it to continue operating without interruption while it resolves its payment dispute with Medicare as expeditiously as possible. As of December 31, 2013, this dealer owed to the Company approximately $240,000 in pre-petition accounts receivable. In July 2014, pursuant to an arrangement approved by the Bankruptcy Court, this pre-petition accounts receivable balance was paid in full. The Company continues to fill this dealer's post-petition orders, with payments received in accordance with our normal terms.
	On April 4, 2014, the Company received a notice from Environmental Research Center, a California non-profit corporation, alleging that the Company failed to include a warning notice related to lead content on labels of certain nutritional products sold in California as required under California's Safe Drinking Water and Toxic Enforcement Act of 1986 ("Proposition 65"). Sales of products identified in this notice totaled approximately $60,000 for the period covered by the notice. This non-profit organization seeks an agreement from the Company to reformulate or label the listed products distributed in California in accordance with Proposition 65 and pay an appropriate civil penalty related to sales in California of allegedly improperly labeled products since April 4, 2011. The Company is continuing to assess this matter and has established a reserve in an amount deemed adequate by management based on the facts and circumstances of the case.

Segments_and_Geographic_Area

Segments and Geographic Area	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segments and Geographic Area	SEGMENTS AND GEOGRAPHIC AREA
	The Company's segments are based on the organization structure that is used by management for making operating and investment decisions and for assessing performance.  Based on this management approach, the Company has two operating segments: Nutritional Products and Medical Products.
	The Nutritional Products segment manufactures and distributes a line of approximately 100 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products.  Nutritional Products are marketed under the “RBC Life” brand name through subsidiaries in North America and Southeast Asia.  These products are distributed in North America and Southeast Asia by a network of independent Associates and by licensees operating in certain other international markets.  For the most part, licensees also market the Nutritional Products in their respective territories through a network of independent Associates.
	The Medical Products segment markets a line of over 35 wound care products under the MPM Medical brand name through a U.S. subsidiary operating primarily in the U.S.  The wound care products are distributed to hospitals, nursing homes, home health care agencies, clinics and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.
	The accounting policies of the segments are the same as those described in Note B. The Company evaluates the performance of its segments primarily based on operating profit.  All intercompany transactions have been eliminated, and intersegment revenues are not significant.  In calculating operating profit (loss) for these two segments, administrative expenses incurred that are common to the two segments are allocated on a usage basis.
	Segment information is as follows (in thousands):
		Nutritional Products			Medical Products		Consolidated
	Year ended December 31, 2014
	Net sales	$	22,073		$	6,197	$	28,270
	Depreciation and amortization	519			61		580
	Operating profit (loss)	(734		)	109		(625		)
	Capital expenditures	1,074			—		1,074
	Total assets	13,192			2,804		15,996
	Year ended December 31, 2013
	Net sales	$	19,084		$	6,387	$	25,471
	Depreciation and amortization	527			61		588
	Operating profit (loss)	(792		)	167		(625		)
	Capital expenditures	267			—		267
	Total assets	13,861			3,673		17,534
	Financial information summarized geographically based on the customer’s ordering location for the years ended December 31, 2014 and 2013 is listed below (in thousands):
		Net Sales			Long-lived Assets
	Year ended December 31, 2014
	Domestic	$	8,974		$	6,309
	Russia/Eastern Europe	10,633			—
	Canada	1,223			465
	Southeast Asia	7,245			375
	All others	195			—
	Totals	$	28,270		$	7,149
	Year ended December 31, 2013
	Domestic	$	9,656		$	5,862
	Russia/Eastern Europe	11,657			—
	Canada	1,530			511
	Southeast Asia	2,454			143
	All others	174			—
	Totals	$	25,471		$	6,516
	Significant Customers - The Company recorded sales to CCI, a licensee of the Company, in the amount of $10,633,000 and $11,657,000 for the years ended December 31, 2014 and 2013, respectively.  The Company also recorded sales to a medical/surgical dealer (see Note M) in the amount of $2,814,000 and $2,807,000 for the years ended December 31, 2014 and 2013, respectively.  In no other case did a customer of the Company account for more than 10% of net sales for the years ended December 31, 2014 or 2013.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	LOSS PER SHARE
	Summarized basic and diluted loss per common share were calculated as follows:
		Net Loss			Shares	Per Share
	Year ended December 31, 2014
	Basic loss per common share	$	(602,811	)	2,212,350	($0.27)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(602,811	)	2,212,350	($0.27)
	Year ended December 31, 2013
	Basic loss per common share	$	(500,005	)	2,218,757	($0.23)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(500,005	)	2,218,757	($0.23)
	For 2014 and 2013, the number of stock options that were outstanding but not included in the computation of diluted loss per common share because their exercise price was greater than the average market price of our common stock or were otherwise anti-dilutive, was approximately 51,000 and 75,000, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS
	Debt Guarantees – The Company’s Chairman of the Board has guaranteed a mortgage note of the Company.  The balance of this note was $1,136,000 at December 31, 2014.
	Customer Arrangement - The Company's principle licensee is CCI. The president of CCI beneficially owned approximately 18% of the Company’s outstanding common stock at December 31, 2014 and was a member of the Company’s Board of Directors until June 2004. The Company recorded sales to CCI in the amount of $10,633,000 and $11,657,000 for the years ended December 31, 2014 and 2013, respectively.
	In August 2014, the Company entered into a two-year exclusive distributorship agreement with CCI. This agreement replaced the 10-year exclusive distributorship agreement between the parties that automatically renewed for a one-year term following expiration of the initial term in July 2014. Pursuant to the new agreement, CCI’s exclusive territory now includes Russia and other countries located primarily in Europe and Central Asia, which represents an expansion of the territory set forth in the former agreement. Under the former agreement, CCI distributed products in a territory comprised mainly of Russia and Eastern Europe.
	Also under the former agreement, in consideration of the grant of certain rights, CCI paid the Company a monthly royalty calculated as a percentage of its sales of the Company's products. Under the new agreement, in lieu of a royalty, the prices at which products are sold to CCI were marked up as of the effective date of the agreement to include the royalty so that no additional royalty is due upon the sale of the Company's products by CCI. To affect the transition of royalty calculations from the previous agreement to the new agreement, the Company recognized royalties of $941,000 on a one-time basis, which royalties will be paid over an 18-month period beginning October 2014. Of this $941,000 in royalties, approximately $476,000 was recorded as royalty revenue in the third quarter of 2014 while the remainder was recorded as deferred revenue pending shipment of the related products. Pursuant to the previous agreement, CCI paid royalties to the Company for the years ended December 31, 2014 and 2013 in the amount of $1,444,000 and $1,801,000, respectively, which are included in sales.
	In accordance with the terms of both the new agreement and previous agreement, CCI is required to pay a deposit at the time it places an order and then pay the balance when products are segregated in the Company's warehouse for its account. Under the new agreement, CCI is required to pay a 25% deposit with each order. Under the previous agreement, CCI was required to pay a 50% deposit with each order. Deferred revenue associated with CCI’s account, which primarily includes deposits for orders placed with he Company and payments for products held by the Company for shipment to CCI at a later date, totaled $2,138,000 and $3,682,000 at December 31, 2014 and 2013, respectively.
	Associate Sales and Marketing System - In December 2013, the Company engaged GSAT, Inc. ("GSATi") to develop a new Associate sales and marketing system, which the Company expects to be deployed during the first quarter of 2015. The Company has made payments to GSATi under the contract totaling approximately $740,000, which represents the full amount due for the contracted system. The founder and CEO of GSATi is a member of the Company's Board of Directors.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (unaudited)	QUARTERLY FINANCIAL DATA (UNAUDITED)
	Quarterly financial data for the years ended December 31, 2014 and 2013 is summarized as follows:
		Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
		(Unaudited - In thousands, except per share data)
	2014
	Net sales	$	5,713		$	7,885		$	7,515		$	7,157
	Gross profit	3,182			4,122			4,282			4,052
	Net loss	(378		)	(7		)	(124		)	(94		)
	Loss per share:
	Basic	$	(0.17	)	$	(0.00	)	$	(0.06	)	$	(0.04	)
	Diluted	(0.17		)	(0.00		)	(0.06		)	(0.04		)
	2013
	Net sales	$	5,691		$	6,694		$	6,640		$	6,446
	Gross profit	2,973			2,971			3,036			3,032
	Net loss	(8		)	(147		)	(142		)	(203		)
	Loss per share:
	Basic	$	(0.00	)	$	(0.07	)	$	(0.06	)	$	(0.09	)
	Diluted	(0.00		)	(0.07		)	(0.06		)	(0.09		)

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation and Reporting	Principles of Consolidation and Reporting - The consolidated financial statements include the accounts of RBC and its wholly owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.  Subsequent events were evaluated through the issuance date of the financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents - The Company regularly holds cash deposits in foreign bank accounts in connection with its foreign operations.  At December 31, 2014 and 2013, $833,000 and $1,164,000, respectively, were held in foreign banks. For purposes of the consolidated statements of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company includes in its cash and cash equivalents credit card payments due from its credit card processors.
Accounts Receivable	Accounts Receivable - The Company’s accounts receivable arise in the normal course of business and primarily relate to sales of Medical Products to various businesses and individuals.  Accounts receivable are generally due within 30, 45 or 60 days and are stated at amounts due from customers net of an allowance for doubtful accounts.
	Accounts outstanding longer than the contractual payment terms are considered past due.  The Company determines its allowance by considering a number of factors including the length of time accounts are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company and the industry as a whole.  The Company charges accounts receivable against the allowance when they become uncollectible, and any payments subsequently received on such accounts are credited to the allowance for doubtful accounts.
Inventories	Inventories - Inventories consisting of raw materials and bulk products, packaging materials and finished goods are stated at the lower of cost or market.  The cost of inventories is determined using the first in, first out method.
Property and Equipment	Property and Equipment - Property and equipment are recorded at cost. Depreciation and amortization are provided over the estimated useful lives of the related assets, principally on the straight-line method, ranging from three to 25 years.
Intangible Assets and Amortization	Intangible Assets and Amortization - Goodwill and other intangible assets with indefinite useful lives are not amortized, but are reviewed annually for impairment or when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Intangible assets with finite lives are amortized over their useful lives.  At December 31, 2014 and 2013, the Company’s intangible assets with finite lives consisted of copyrights, trademarks and other registrations, a business license and other intangibles, all of which are amortized over an average life of 19 years except the business license, which is being amortized over a life of one year.
	The Company has designated year end as the date of its annual goodwill impairment test.  The Company tests goodwill for impairment by comparing the carrying value of a reporting unit, including goodwill, to the fair value of the unit.  Fair value is determined by estimating the present value of future cash flows and the value of comparable companies based on sales multiples.  An impairment loss would be recognized if the carrying value of a reporting unit exceeds the implied fair value.  To date, the Company has not recognized any impairment losses related to the carrying value of its goodwill.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets - Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue - Sales are recorded when products are shipped, which is the point the risks and rewards of ownership pass to the customer. Sales include amounts billed to customers for shipping and handling and are recorded net of sales taxes.  The Company generally requires a cash or credit card payment at the point of sale for Nutritional Products sold to its Associates.  With regard to orders received from its third-party licensees, the Company generally requires the licensee to make a cash deposit equal to 25% to 50% of the order at the time an order is placed, and to pay the remaining balance when the products are segregated in the Company's warehouse and ready to ship; however, sales are not recognized until the products are shipped. Deposits and payments received for unshipped products are recorded as “deferred revenue.”
	Prior to August 1, 2014, the Company’s agreement with its principle licensee, Coral Club International, Inc. ("CCI"), provided that CCI pay to the Company a monthly royalty, which was calculated as a specified percentage of its sales, as defined, in the territory covered by the license agreement.
Distributor Commissions	Distributor Commissions - Distributor commissions consist primarily of commissions paid to Associates in accordance with the Associate compensation plan.  These commissions are calculated based on the total monthly sales by the Associate and his or her downline organization.  Most commissions are paid to Associates monthly.  Sales incentives paid to Associates that represent rebates are recorded as a reduction of sales rather than distributor commission expense.  Associates can earn rebates if the amount of their personal monthly sales exceeds a threshold amount set forth under the Associate compensation plan
Income Taxes	Income Taxes - The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred income tax assets and liabilities are provided based on the difference between the financial statement and tax bases of assets and liabilities as measured by the currently enacted tax rates in effect for the years in which these differences are expected to reverse. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities. An allowance against deferred tax assets is recorded in whole or in part when it is more likely than not that such tax benefits will not be realized.
Earnings (Loss) Per Share	Earnings (Loss) Per Share - Basic earnings (loss) per common share is based upon the weighted average number of common shares outstanding during each period presented. Diluted earnings (loss) per share is based upon the weighted average number of common shares outstanding and, when dilutive, common shares issuable for stock options.
Accounting Estimates	In preparing financial statements in conformity with accounting principles generally accepted in the U.S. ("US GAAP"), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues during the reporting period.  Actual results could differ from those estimates.
Financial Instruments	Financial Instruments - The carrying value of cash, interest-bearing deposits, accounts receivable and payable, accrued liabilities and lines of credit approximate fair value due to the short-term maturities of these assets and liabilities. Fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.
Segment Information	Segment Information - The Company’s operations involve two operating segments:  the Nutritional Products segment and the Medical Products segment.  Nutritional Products are developed and distributed to a network of independent Associates operating primarily in North America, Southeast Asia and Australia and to licensees operating in certain other countries.  Medical Products are developed and sold primarily throughout the U.S. through medical/surgical supply dealers and pharmaceutical distributors to medical institutions such as hospitals, nursing homes and pharmacies.
Product Return Policy	Product Return Policy - Up to one year from the date of purchase, Nutritional Products that are unused and resalable may be returned by an Associate for a refund equal to 100% of the sales price to the Associate less a 10% restocking fee and commissions paid. The return of product by an Associate, other than product damaged at the time of receipt, may result in cancellation of the distributorship. Generally, unused Medical Products may be returned up to six months from date of purchase for a refund equal to 100% of the sales price less a 25% restocking fee.  Returned products damaged during shipment are replaced by the Company.  Nutritional Products purchased by licensees may not be returned to the Company for a refund except in the case of a product defect.
Advertising	Advertising - Advertising expense is charged to operations when incurred.
Translation of Foreign Currencies	Translation of Foreign Currencies - All assets and liabilities of foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect at the consolidated balance sheet date.  Revenue and expense accounts are translated at weighted average exchange rates. Translation gains and losses are reflected as a component of other comprehensive income in shareholders' equity.  Gains and losses on foreign currency transactions are included in the consolidated statements of comprehensive income.
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) - Other comprehensive income (loss) refers to revenues, expenses, gains and losses that under US GAAP are included in comprehensive income (loss) but are excluded from net earnings (loss) as the amounts are recorded directly as an adjustment to shareholders’ equity.  The Company’s other comprehensive income is attributed to translation gains or losses of foreign currencies.
Share-based Compensation	Share-Based Compensation - The Company recognizes share-based compensation expense based on the fair value of share-based awards.  Share-based compensation is estimated at the grant date based on the fair value of the awards expected to vest and recognized as expense ratably over the requisite service period of the award. The Company uses the Black-Scholes valuation model to estimate fair value of share-based awards, which requires various assumptions including estimating stock price volatility, risk-free interest rate and expected life.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company does not believe ASU No. 2014-09 will have a material effect on its financial position and results of operations.
	In August 2014, FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern. ASU No. 2014-15 provides guidance regarding management’s responsibility to evaluate whether there exists substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. ASU No. 2014-15 is effective for annual reporting periods beginning after December 15, 2016, and interim periods thereafter. The Company does not believe ASU No. 2014-15 will have a material effect on its financial position and results of operations.

Accounts_Receivable_Tables

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Schedule of Accounts Receivable	At December 31, 2014 and 2013, accounts receivable consist of the following:
		2014			2013
	Accounts receivable
	Trade	$	1,321,062		$	914,287
	Other	—			21,000
	Total	1,321,062			935,287
	Less allowance for doubtful accounts	35,219			28,000
	Net accounts receivable	$	1,285,843		$	907,287
Schedule of Allowance for Doubtfull Accounts	Changes in the Company’s allowance for doubtful accounts for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Beginning balance	$	28,000		$	27,417
	Bad debt provision	7,263			9,926
	Accounts written off	(44		)	(9,343		)
	Ending balance	$	35,219		$	28,000
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. In accordance with an arrangement approved by the Bankruptcy Court, the pre-petition accounts receivable balance of approximately $240,000 that was outstanding at December 31, 2013 was paid in full during 2014.
	As more fully described in Note P, in August 2014, the Company entered into a new two-year exclusive distributorship agreement with CCI pursuant to which the royalty calculations were restructured. Under the previous agreement, CCI paid the Company a monthly royalty calculated as a percentage of its sales of the Company's products. Under the new agreement, in lieu of the monthly royalty, the prices at which products are sold to CCI were marked to include the royalty so that no additional royalty will be due upon the sale of the Company's products by CCI. To affect the transition of royalty calculations from the previous agreement to the new agreement, the Company recorded a royalty receivable of $941,000, which is to be paid over an 18-month period beginning October 2014 in the amount of approximately $52,000 per month. The portion of this royalty receivable due after December 31, 2015 is classified as "Other assets" in the accompanying consolidated balance sheet.

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	At December 31, 2014 and 2013, inventories, which are stated at the lower of cost or market, consist of the following:
		2014		2013
	Raw materials and bulk products	$	370,333	$	371,863
	Packaging materials	253,700		135,138
	Finished goods	4,175,050		4,634,508
		$	4,799,083	$	5,141,509

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Prepaid Expense, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	At December 31, 2014 and 2013, prepaid expenses and other current assets consist of the following:
		2014		2013
	Advances to Associate	$	—	$	339,603
	Advance payments to suppliers	151,365		202,682
	Certificates of deposit – restricted	73,270		79,909
	Prepaid insurance and other	239,385		171,354
	Total	$	464,020	$	793,548

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	At December 31, 2014 and 2013, property and equipment consist of the following:
		2014		2013
	Building and improvements	$	4,042,897	$	3,912,449
	Computer software and office equipment	3,536,399		2,592,382
	Warehouse equipment	254,034		254,034
	Automotive equipment	14,717		14,717
		7,848,047		6,773,582
	Less accumulated depreciation and amortization	4,305,724		3,745,677
		3,542,323		3,027,905
	Land	1,141,173		1,141,173
		$	4,683,496	$	4,169,078

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Other Intangible Assets [Abstract]
Summary of Goodwill Balances	Goodwill balances are summarized as follows:
			Gross				Accumulated
			Carrying				Amortization
			Value
	Balance, January 1, 2013		$	3,435,305			$	(1,137,285	)
	Currency translation adjustment		(67,442		)		32,880
	Balance, December 31, 2013		3,367,863				(1,104,405		)
	Currency translation adjustment		(82,173		)		40,062
	Balance, December 31, 2014		$	3,285,690			$	(1,064,343	)
Schedule of Other Intangible Assets	At December 31, 2014 and 2013, other intangible assets consist of the following:
			2014									2013
			Average		Gross				Accumulated			Average	Gross		Accumulated
			Life		Carrying				Amortization			Life	Carrying		Amortization
			(years)		Value							(years)	Value
	Copyrights, trademarks and other registrations		19		$	99,100			$	(70,690	)	19	$	99,100	$	(65,405	)
	Business license		1		37,193				(29,240		)	0	—		—
	Other		19		12,600				(8,988		)	19	12,600		(8,316		)
					$	148,893			$	(108,918	)		$	111,700	$	(73,721	)
Schedule of Aggregate Estimated Amortization Expense	The aggregate estimated amortization expense for other intangible assets is as follows:
	Year ended December 31,
	2015	$	13,910
	2016	5,957
	2017	5,957
	2018	5,957
	2019	5,957
	Thereafter	2,237
		$	39,975

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities	At December 31, 2014 and 2013, accrued liabilities consist of the following:
		2014		2013
	Distributor commissions	$	867,336	$	507,365
	Salaries and wages	468,192		502,303
	Sales and property taxes	73,954		83,159
	Interest	7,339		8,711
	Other	3,229		55,280
	Total	$	1,420,050	$	1,156,818

LongTerm_Obligations_Tables

Long-Term Obligations (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Long-term Obligations	At December 31, 2014 and 2013, long-term obligations consist of the following:
			2014		2013
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board of Directors		$	1,136,347	$	1,348,821
	Less – current maturities		229,538		212,474
			$	906,809	$	1,136,347
Schedule of Maturities of Long-term Debt	Long-term obligation payments payable in the next five years are as follows:
	Year ended December 31,
	2015	$	229,538
	2016	247,973
	2017	267,889
	2018	289,403
	2019	101,544
		$	1,136,347

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation [Abstract]
Schedule of Fair Value of Option Grants	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Year Ended December 31,
		2014		2013
		-1
	Weighted average expected life (years)	0		4.5
	Risk-free interest rate	—%		1.40%
	Expected volatility	—%		261.00%
	Expected dividend yield	—%		—%
	______________________
	(1) There were no option grants during this period.
Schedule of Stock Option Activity	A summary of stock option activity for the two years ended December 31, 2014 is as follows:
		Options			Weighted-			Weighted-Average		Aggregate
					Average Exercise			Remaining		Intrinsic
					Price per Share			Contractual Term		Value
								(in years)
	Outstanding, January 1, 2013	86,126			$	4
	Granted	2,160			1.17
	Exercised	—			—
	Forfeited/canceled	(18,890	)		3.47
	Outstanding, December 31, 2013	69,396			4
	Granted	—			—
	Exercised	—			—
	Forfeited/canceled	(18,500	)		3.29
	Outstanding, December 31, 2014	50,896			$	4.35		2.8		$	—
	Exercisable, December 31, 2014	50,896			$	4.35		2.8		$	—
Schedule of Nonvested Share Activity	A summary of the status of the Company’s non-vested stock options as of December 31, 2014 and 2013, and changes during the year then ended, is presented below:
		Year Ended December 31,
		2014						2013
		Shares			Weighted Average			Shares			Weighted Average
					Grant Date Fair						Grant Date Fair
					Value per Share						Value per Share
	Non-vested stock options at January 1,	14,750			$	2.68		19,976			$	2.9
	Non-vested stock options granted	—			—			2,160			1.14
	Vested stock options	—			—			(7,386	)		2.92
	Forfeited stock options	(14,750	)		2.68			—			—
	Non-vested stock options at December 31,	—			$	—		14,750			$	2.68
Schedule of Grant Date Intrinsic Value	Additional information related to stock options granted, vested and exercised for the two years ended December 31, 2014 is a follows:
		Year Ended December 31,
		2014				2013
	Grant date fair value of stock options granted	$	—			$	2,471
	Grant date fair value of stock options vested	—				21,586
	Intrinsic value of stock options exercised	—				—

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Reconciliation to tax computed at Federal stautory rate	The income tax benefit reconciled to the tax computed at the statutory federal rate of 34% is as follows:
		Year Ended December 31,
		2014			2013
	Federal income tax benefit at statutory rate	$	(245,135	)	$	(250,322	)
	State income taxes, net of federal benefit	1,682			(755		)
	Share-based compensation	716			6,759
	Effect of foreign operations, net of foreign tax credits	114,232			42,340
	R&D tax credits recognized	—			(35,417		)
	Other, net	10,331			1,159
	Income tax benefit	$	(118,174	)	$	(236,236	)
Deferred tax assets and liabilities	Deferred tax assets and liabilities at December 31, 2014 and 2013 are comprised of the following:
		December 31,
		2014			2013
	Deferred tax assets related to:
	Inventories	$	281,155		$	289,818
	Accounts receivable and other assets	12,327			9,800
	Accrued liabilities	83,443			89,816
	Tax loss and tax credit carryforwards	603,018			583,787
	Other	16,446			16,349
		996,389			989,570
	Valuation allowance	(196,661		)	(214,479		)
	Net deferred tax assets	799,728			775,091
	Deferred tax liabilities related to:
	Property and equipment	(363,119		)	(462,221		)
	Intangible assets	(616,124		)	(610,890		)
	Deferred tax liabilities	(979,243		)	(1,073,111		)
	Net deferred tax liabilities	$	(179,515	)	$	(298,020	)
	Net current deferred tax assets	$	376,925		$	429,640
	Net long-term deferred tax liabilities	(556,440		)	(727,660		)
		$	(179,515	)	$	(298,020	)
Income tax expense (benefit) for continuing operations	Income tax expense (benefit) consists of the following:
		Year Ended December 31,
		2014			2013
	Current
	Federal	$	6,999		$	2,941
	Foreign	—			(3,717		)
	Deferred
	Federal	21,816			(196,484		)
	Foreign	(146,989		)	(38,976		)
	Income tax benefit	$	(118,174	)	$	(236,236	)

Commitments_and_Contingencies_1

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	uture minimum payments under non-cancelable operating leases are as follows:
	Year ended December 31,
	2015	$	452,354
	2016	354,981
	2017	135,813
	2018	7,029
		$	950,177

Segments_and_Geographic_Area_T

Segments and Geographic Area (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Information	Segment information is as follows (in thousands):
		Nutritional Products			Medical Products		Consolidated
	Year ended December 31, 2014
	Net sales	$	22,073		$	6,197	$	28,270
	Depreciation and amortization	519			61		580
	Operating profit (loss)	(734		)	109		(625		)
	Capital expenditures	1,074			—		1,074
	Total assets	13,192			2,804		15,996
	Year ended December 31, 2013
	Net sales	$	19,084		$	6,387	$	25,471
	Depreciation and amortization	527			61		588
	Operating profit (loss)	(792		)	167		(625		)
	Capital expenditures	267			—		267
	Total assets	13,861			3,673		17,534
Summary of Financial Information by Geographic Segment	Financial information summarized geographically based on the customer’s ordering location for the years ended December 31, 2014 and 2013 is listed below (in thousands):
		Net Sales			Long-lived Assets
	Year ended December 31, 2014
	Domestic	$	8,974		$	6,309
	Russia/Eastern Europe	10,633			—
	Canada	1,223			465
	Southeast Asia	7,245			375
	All others	195			—
	Totals	$	28,270		$	7,149
	Year ended December 31, 2013
	Domestic	$	9,656		$	5,862
	Russia/Eastern Europe	11,657			—
	Canada	1,530			511
	Southeast Asia	2,454			143
	All others	174			—
	Totals	$	25,471		$	6,516

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings (Loss) Per Common Share	Summarized basic and diluted loss per common share were calculated as follows:
		Net Loss			Shares	Per Share
	Year ended December 31, 2014
	Basic loss per common share	$	(602,811	)	2,212,350	($0.27)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(602,811	)	2,212,350	($0.27)
	Year ended December 31, 2013
	Basic loss per common share	$	(500,005	)	2,218,757	($0.23)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(500,005	)	2,218,757	($0.23)

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Quarterly financial data for the years ended December 31, 2014 and 2013 is summarized as follows:
		Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
		(Unaudited - In thousands, except per share data)
	2014
	Net sales	$	5,713		$	7,885		$	7,515		$	7,157
	Gross profit	3,182			4,122			4,282			4,052
	Net loss	(378		)	(7		)	(124		)	(94		)
	Loss per share:
	Basic	$	(0.17	)	$	(0.00	)	$	(0.06	)	$	(0.04	)
	Diluted	(0.17		)	(0.00		)	(0.06		)	(0.04		)
	2013
	Net sales	$	5,691		$	6,694		$	6,640		$	6,446
	Gross profit	2,973			2,971			3,036			3,032
	Net loss	(8		)	(147		)	(142		)	(203		)
	Loss per share:
	Basic	$	(0.00	)	$	(0.07	)	$	(0.06	)	$	(0.09	)
	Diluted	(0.00		)	(0.07		)	(0.06		)	(0.09		)

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 01, 2014	Aug. 09, 2013	Aug. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Oct. 01, 2014	Dec. 31, 2012
					segment
Property, Plant and Equipment [Line Items]
Cash and cash equivalents				$1,921,349	$1,921,349	$3,745,684		$3,896,087
Intangible Assets useful life					19 years
Reverse stock split conversion ratio		50000.00%
Stock split cash paid per share (usd per share)		$0.17
Conversion ratio		50
Cash deposit required from third-party licensees at time of order (percent)					25.00%	50.00%
Duration of license agreement			2 years
Royalty receivable	941,000						941,000
Period over which royalty is payable	18 months
Royalty revenue				476,000	1,444,000	1,801,000
Distributor commissions					324,000	281,000
Fair value of fixed-rate long-term debt				1,226,000	1,226,000	1,469,000
Amount fair value exceeds carrying value				90,000	90,000	120,000
Carrying amount of fixed-rate long-term debt				1,136,347	1,136,347	1,349,000
Number of operating segments					2
Advertising expense					37,000	44,000
Gain (loss) on foreign currency transaction					-220,000	-66,000
Nutritional Products [Member]
Property, Plant and Equipment [Line Items]
Duration resaleable returned items are fully refunded					1 year
Refund percent of sales price					100.00%
Restocking fee (percent)					10.00%
Medical Products [Member]
Property, Plant and Equipment [Line Items]
Duration resaleable returned items are fully refunded					6 months
Refund percent of sales price					100.00%
Restocking fee (percent)					25.00%
Foreign Bank [Member]
Property, Plant and Equipment [Line Items]
Cash and cash equivalents				$833,000	$833,000	$1,164,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives					3 years
Cash deposit required from third-party licensees at time of order (percent)					25.00%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives					25 years
Cash deposit required from third-party licensees at time of order (percent)					50.00%

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Oct. 01, 2014	Aug. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Oct. 01, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Royalty receivable	$941,000				$941,000
Period over which royalty is payable	18 months
Royalty Agreement, Monthly Payment Receivable	52,000				52,000
Accounts receivable			1,321,062	935,287
Less allowance for doubtful accounts			35,219	28,000
Net accounts receivable			1,285,843	907,287
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for doubtful accounts, beginning balance			28,000	27,417
Bad debt provision			7,263	9,926
Accounts written off			-44	-9,343
Allowance for doubtful accounts, ending balance			35,219	28,000
Pre-Petition accounts receivable from major customer in bankruptcy court			240,000	240,000
Duration of license agreement		2 years
Trade [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable			1,321,062	914,287
Other [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable			$0	$21,000

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials and bulk products	$370,333	$371,863
Packaging materials	253,700	135,138
Finished goods	4,175,050	4,634,508
Inventories	$4,799,083	$5,141,509

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	7 Months Ended
	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Prepaid Expenses and Other Current Assets [Line Items]
Advances to Associate		$0	$339,603
Advance payments to suppliers		151,365	202,682
Certificates of deposit b restricted		73,270	79,909
Prepaid insurance and other		239,385	171,354
Total		464,020	793,548
Certificates of deposit		73,000	80,000
Property and equipment, net of accumulated depreciation		4,683,496	4,169,078
HONG KONG
Prepaid Expenses and Other Current Assets [Line Items]
Net advances under the agreement	403,000
Other Assets				43,000
Leasehold Improvements and Furniture and Fixtures [Member] | HONG KONG
Prepaid Expenses and Other Current Assets [Line Items]
Property and equipment, net of accumulated depreciation				$104,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$7,848,047	$6,773,582
Less: accumulated depreciation	4,305,724	3,745,677
Property and equipment, net of accumulated depreciation	4,683,496	4,169,078
Depreciation expense	542,700	582,300
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,042,897	3,912,449
Computer Software and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,536,399	2,592,382
warehouse equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	254,034	254,034
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	14,717	14,717
Property, Plant and Equipment, Other Types [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net of accumulated depreciation	3,542,323	3,027,905
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net of accumulated depreciation	$1,141,173	$1,141,173

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Summary of Goodwill Balances) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Gross Carrying Value, Beginning Balance	$3,367,863	$3,435,305
Gross Carrying Value, Currency translation adjustment	-82,173	-67,442
Gross Carrying Value, Ending Balance	3,285,690	3,367,863
Accumulated Amortization, Beginning Balance	-1,104,405	-1,137,285
Currency translation adjustment	40,062	32,880
Accumulated Amortization, Beginning Balance	($1,064,343)	($1,104,405)

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Summary of Other Intangible Assets) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Average Life (years)	19 years
Gross Carrying Value	$148,893	$111,700
Accumulated Amortization	-108,918	-73,721
Amortization expense	37,200	6,000
Copyrights, trademarks and other registrations [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Average Life (years)	19 years	19 years
Gross Carrying Value	99,100	99,100
Accumulated Amortization	-70,690	-65,405
Business License [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Average Life (years)	1 year	0 years
Gross Carrying Value	37,193	0
Accumulated Amortization	-29,240	0
Other [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Average Life (years)	19 years	19 years
Gross Carrying Value	12,600	12,600
Accumulated Amortization	($8,988)	($8,316)

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Aggregate Estimated Amortization) (Details) (USD $)	Dec. 31, 2014
Goodwill and Other Intangible Assets [Abstract]
2015	$13,910
2016	5,957
2017	5,957
2018	5,957
2019	5,957
Thereafter	2,237
Aggregate estimated amortization expense	$39,975

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]
Distributor commissions	$867,336	$507,365
Salaries and wages	468,192	502,303
Sales and property taxes	73,954	83,159
Interest	7,339	8,711
Other	3,229	55,280
Total	$1,420,050	$1,156,818

LongTerm_Obligations_Details

Long-Term Obligations (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Companybs Chairman of the Board of Directors	$1,136,347	$1,348,821
Current maturities of long-term obligations	229,538	212,474
Long-term obligations, less current maturities	906,809	1,136,347
Interest rate (as a percentage)	7.75%
Monthly installment payments	25,797
Long-term Debt, Fiscal Year Maturity [Abstract]
2015	229,538
2016	247,973
2017	267,889
2018	289,403
2019	101,544
Total long-term debt	$1,136,347	$1,349,000

ShareBased_Compensation_Summar

Share-Based Compensation (Summary of Fair Value of Option Grants) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 04, 2003	Jul. 01, 1998	Jun. 01, 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$2,100	$20,600
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Weighted average expected life (years)	0 years	4 years 6 months
Risk-free interest rate	0.00%	1.00%
Expected volatility	0.00%	261.00%
Expected dividend yield	0.00%	0.00%
1998 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved			350,000	50,000
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved					250,000
Minimum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award term period	5 years
Maximum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	5 years
Award term period	9 years

ShareBased_Compensation_Summar1

Share-Based Compensation (Summary of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Options, Outstanding [Roll Forward]
Options, Beginning Balance Outstanding	69,396	86,126
Options, Granted	0	2,160
Options, Exercised	0	0
Options, Forfeited/canceled	-18,500	-18,890
Options, Ending Balance Outstanding	50,896	69,396
Options, Exercisable	50,896
Outstanding, Weighted-Average Exercise Price per Share [Roll Forward]
Weighted-Average Exercise Price per Share, Beginning Balance Outstanding	$4	$4
Weighted-Average Exercise Price per Share, Granted	$0	$1.17
Weighted-Average Exercise Price per Share, Exercised	$0	$0
Weighted-Average Exercise Price per Share, Forfeited/canceled	$3.29	$3.47
Weighted-Average Exercise Price per Share, Ending Balance Outstanding	$4.35	$4
Weighted-Average Exercise Price per Share, Exercisable	$4.35
Weighted-Average Remaining Contractual Term, Outstanding	2 years 9 months 18 days
Weighted-Average Remaining Contractual Term, Exercisable	2 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding	$0
Aggregate Intrinsic Value, Exercisable	$0

ShareBased_Compensation_Summar2

Share-Based Compensation (Summary of Non-vested Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Non-vested Stock Options, Number of Shares [Roll Forward]
Shares, Non-vested stock options, Beginning Balance	14,750	19,976
Shares, Non-vested stock options granted	0	2,160
Shares, Vested stock options	0	-7,386
Shares, Forfeited stock options	-14,750	0
Shares, Non-vested stock options, Ending Balance	0	14,750
Non-vested Stock Options, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Beginning Balance	$2.68	$2.90
Weighted Average Grant Date Fair Value per Share, Non-vested stock options granted	$0	$1.14
Weighted Average Grant Date Fair Value per Share, Vested stock options	$0	$2.92
Weighted Average Grant Date Fair Value per Share, Forfeited stock options	$2.68	$0
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Ending Balance	$0	$2.68

ShareBased_Compensation_Value_

Share-Based Compensation (Value of Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Grant date fair value of stock options granted	$0	$2,471
Grant date fair value of stock options vested	0	21,586
Intrinsic value of stock options exercised	$0	$0

Income_TaxesReconciliation_Det

Income Taxes-Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal statutory income tax rate (percent)	34.00%
Income Tax Expense (Benefit), Income Tax Reconciliation [Abstract]
Federal income tax benefit at statutory rate	($245,135)	($250,322)
State income taxes, net of federal benefit	1,682	-755
Share-based compensation	716	6,759
Effect of foreign operations, net of foreign tax credits	114,232	42,340
R&D tax credits recognized	0	-35,417
Other, net	10,331	1,159
Income tax benefit	($118,174)	($236,236)

Income_TaxesDeferred_Tax_Asset

Income Taxes-Deferred Tax Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets related to:
Inventories	$281,155	$289,818
Accounts receivable and other assets	12,327	9,800
Accrued liabilities	83,443	89,816
Tax loss and tax credit carryforwards	603,018	583,787
Other	16,446	16,349
Deferred tax assets, gross	996,389	989,570
Valuation allowance	-196,661	-214,479
Net deferred tax assets	799,728	775,091
Deferred tax liabilities related to:
Property and equipment	-363,119	-462,221
Intangible assets	-616,124	-610,890
Deferred tax liabilities	-979,243	-1,073,111
Net deferred tax liabilities	-179,515	-298,020
Net current deferred tax assets	376,925	429,640
Net long-term deferred tax liabilities	-556,440	-727,660
U.S. Federal net operating loss carryforward	73,000
Domestic Tax Authority [Member]
Deferred tax liabilities related to:
Operating loss carryforwards, subject to expiration	170,000
Canada [Member] | Foreign Tax Authority [Member]
Deferred tax liabilities related to:
Operating loss carryforwards, subject to expiration	$1,986,000

Income_TaxesComponents_of_Inco

Income Taxes-Components of Income Tax Expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Components of Income Tax Expense (Benefit) [Abstract]
Current Federal	$6,999	$2,941
Current Foreign	0	-3,717
Deferred Federal	21,816	-196,484
Deferred Foreign	-146,989	-38,976
Income tax benefit	($118,174)	($236,236)

Commitments_and_ContingenciesL

Commitments and Contingencies-Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$415,000	$193,000
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	452,354
2016	354,981
2017	135,813
2018	7,029
Total future minimum payments due	$950,177

Commitments_and_ContingenciesE

Commitments and Contingencies-Employee Arrangements (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Eligibility age requirement	18 years
Requisite service period	3 months
Employer matching contribution, percent	10.00%
Cost recognized	$10	$13
Chief executive officer [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Additional term duration	1 year
Salary continuation, percent of annual base salary	50.00%
Salary continuation duration	3 years
President [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Additional term duration	1 year
Salary continuation, percent of annual base salary	50.00%
Chief financial officer [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Salary continuation, percent of annual base salary	50.00%

Commitments_and_ContingenciesL1

Commitments and Contingencies-Litigation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Apr. 11, 2014
Loss Contingencies [Line Items]
Pre-Petition accounts receivable from major customer in bankruptcy court	240	240
Medical Products [Member]
Loss Contingencies [Line Items]
Concentration risk (percent)	45.00%	44.00%
Damages from Product Defects [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss			$60

Segments_and_Geographic_Area_S

Segments and Geographic Area (Summary of Segment Information) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
									segment
Segment Reporting Information [Line Items]
Number of operating segments									2
Net sales	$7,157	$7,515	$7,885	$5,713	$6,000	$7,000	$7,000	$6,000	$28,270,448	$25,470,934
Depreciation and amortization									579,900	588,287
Operating profit (loss)									-625,266	-624,624
Capital expenditures									1,074,436	267,055
Total assets	15,995,944				17,533,510				15,995,944	17,533,510
Nutritional Products [Member]
Segment Reporting Information [Line Items]
Number of products									100
Net sales									22,073,000	19,084,000
Depreciation and amortization									519,000	527,000
Operating profit (loss)									-734,000	-792,000
Capital expenditures									1,074,000	267,000
Total assets	13,192,000				13,861,000				13,192,000	13,861,000
Medical Products [Member]
Segment Reporting Information [Line Items]
Number of products									35
Net sales									6,197,000	6,387,000
Depreciation and amortization									61,000	61,000
Operating profit (loss)									109,000	167,000
Capital expenditures									0	0
Total assets	$2,804,000				$3,673,000				$2,804,000	$3,673,000

Segments_and_Geographic_Area_S1

Segments and Geographic Area (Summary of Financial Information by Geographic Location) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net sales	$7,157	$7,515	$7,885	$5,713	$6,000	$7,000	$7,000	$6,000	$28,270,448	$25,470,934
Long-lived Assets	7,149,000				6,516,000				7,149,000	6,516,000
Domestic [Memeber]
Segment Reporting Information [Line Items]
Net sales									8,974,000	9,656,000
Long-lived Assets	6,309,000				5,862,000				6,309,000	5,862,000
Russia/Eastern Europe [Member]
Segment Reporting Information [Line Items]
Net sales									10,633,000	11,657,000
Long-lived Assets	0				0				0	0
Canada [Member]
Segment Reporting Information [Line Items]
Net sales									1,223,000	1,530,000
Long-lived Assets	465,000				511,000				465,000	511,000
Southeast Asia [Member]
Segment Reporting Information [Line Items]
Net sales									7,245,000	2,454,000
Long-lived Assets	375,000				143,000				375,000	143,000
All others [Member]
Segment Reporting Information [Line Items]
Net sales									195,000	174,000
Long-lived Assets	$0				$0				$0	$0

Segments_and_Geographic_Area_S2

Segments and Geographic Area (Summary Significant Customers) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net sales	$7,157	$7,515	$7,885	$5,713	$6,000	$7,000	$7,000	$6,000	$28,270,448	$25,470,934
Nutritional Products [Member]
Segment Reporting Information [Line Items]
Net sales									22,073,000	19,084,000
Medical Products [Member]
Segment Reporting Information [Line Items]
Net sales									6,197,000	6,387,000
Coral Club International, Inc. [Member]
Segment Reporting Information [Line Items]
Net sales									10,633,000	11,657,000
Medical/Surgical Dealer [Member] | Medical Products [Member]
Segment Reporting Information [Line Items]
Net sales									$2,814,000	$2,807,000

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net loss	$0	$0	$0	$0	$0	$0	$0	$0	($602,811)	($500,005)
Net Earnings (Loss), Diluted									($602,811)	($500,005)
Basic (shares)									2,212,350	2,218,757
Weighted Average Shares, Effect of dilutive stock options									0	0
Diluted (shares)									2,212,350	2,218,757
Basic (usd per share)	($0.04)	($0.06)	$0	($0.17)	($0.09)	($0.06)	($0.07)	$0	($0.27)	($0.23)
Diluted (usd per share)	($0.04)	($0.06)	$0	($0.17)	($0.09)	($0.06)	($0.07)	$0	($0.27)	($0.23)
Antidilutive stock options excluded from earnings per share calculation									51,000	75,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	0 Months Ended			1 Months Ended	3 Months Ended								12 Months Ended
	Oct. 01, 2014	Jul. 31, 2014	Jul. 31, 2013	Aug. 31, 2014	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Oct. 01, 2014
Related Party Transaction [Line Items]
Duration of license agreement				2 years
Net sales					$7,157	$7,515	$7,885	$5,713	$6,000	$7,000	$7,000	$6,000	$28,270,448	$25,470,934
Distribution Agreement, Term		1 year	10 years	2 years
Royalty revenue					476,000								1,444,000	1,801,000
Cash deposit required from third-party licensees at time of order (percent)													25.00%	50.00%
Anticipated total payments under the contract					740,000								740,000
Royalty receivable	941,000														941,000
Period over which royalty is payable	18 months
Coral Club International, Inc. [Member]
Related Party Transaction [Line Items]
Unrecognized license fees					2,138,000				3,682,000				2,138,000	3,682,000
Net sales													10,633,000	11,657,000
Royalty revenue					476,000								1,444,000	1,801,000
Royalty receivable	941,000														941,000
Period over which royalty is payable	18 months
Nutritional Products [Member]
Related Party Transaction [Line Items]
Net sales													22,073,000	19,084,000
Director [Member]
Related Party Transaction [Line Items]
Notes payable					$1,136,000								$1,136,000
President [Member] | Coral Club International, Inc. [Member] | Employee of Major Customer [Member]
Related Party Transaction [Line Items]
Ownership percentage by noncontrolling owners					18.00%								18.00%

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net sales	$7,157	$7,515	$7,885	$5,713	$6,000	$7,000	$7,000	$6,000	$28,270,448	$25,470,934
Gross profit	4,000	4,000	4,000	3,000	3,000	3,000	3,000	3,000	15,638,073	12,011,655
Net loss	$0	$0	$0	$0	$0	$0	$0	$0	($602,811)	($500,005)
Basic (usd per share)	($0.04)	($0.06)	$0	($0.17)	($0.09)	($0.06)	($0.07)	$0	($0.27)	($0.23)
Diluted (usd per share)	($0.04)	($0.06)	$0	($0.17)	($0.09)	($0.06)	($0.07)	$0	($0.27)	($0.23)